Complaint handling backlogs are more than an operational issue — they are a major regulatory risk.
Many medical device companies underestimate how quickly unresolved complaints can escalate into FDA observations, Warning Letters, CAPA issues, and broader quality system concerns.
At RQMIS, we have seen firsthand how complaint backlogs can overwhelm organizations when processes, staffing, and post-market systems are not scaled appropriately.
In one case, RQMIS supported a manufacturer in closing a backlog of more than 12,000 complaints while helping improve the long-term complaint handling process.
FDA Expects Complaints to Be Investigated Promptly
FDA regulations require manufacturers to:
- Review complaints consistently
- Investigate when necessary
- Evaluate reportability
- Identify trends
- Escalate systemic issues into CAPA
When complaints remain open for extended periods, FDA investigators often question whether the company is adequately monitoring product safety and quality.
Backlogs can quickly signal:
- Insufficient quality oversight
- Weak complaint procedures
- Inadequate staffing
- Poor risk management integration
- Lack of management control
Complaint Trends Often Reveal Larger Problems
One unresolved complaint may seem manageable.
Thousands of unresolved complaints often indicate broader systemic issues.
FDA investigators commonly evaluate whether complaints:
- Point to recurring failure modes
- Suggest increased patient risk
- Require CAPA escalation
- Affect risk management files
- Trigger MDR reporting obligations
Without effective trending and investigation processes, companies may miss critical signals tied to product safety or compliance.
Delayed Investigations Increase Regulatory Risk
When complaint investigations are delayed:
- Root causes become harder to identify
- Product history may become incomplete
- MDR reporting timelines may be missed
- CAPA implementation slows down
- Audit exposure increases
FDA often views delayed complaint closure as evidence that the quality system is not functioning effectively.
Post-Market Surveillance Is Under Increasing Scrutiny
FDA and global regulators increasingly expect complaint handling to function as part of a mature Post-Market Surveillance (PMS) system.
This includes:
- Trend analysis
- Escalation procedures
- Risk management updates
- CAPA linkage
- Adverse event evaluation
- Ongoing monitoring activities
Weak complaint handling processes often expose larger PMS deficiencies.
Common Causes of Complaint Backlogs
At RQMIS, some of the most common causes include:
- Rapid company growth
- Limited internal resources
- Manual tracking systems
- Poor complaint categorization
- Weak investigation procedures
- Inconsistent root cause analysis
- Lack of trend analysis tools
- Inadequate staffing during commercialization growth
For software and connected devices, complaint complexity often increases significantly due to cybersecurity, connectivity, and software-related investigations.
Strong Complaint Handling Systems Reduce Risk
Effective complaint handling systems should:
- Standardize investigations
- Support trend analysis
- Feed directly into CAPA
- Update risk management activities
- Improve audit readiness
- Support regulatory reporting compliance
Most importantly, they help companies identify and address product quality issues before they become larger regulatory or safety problems.
Final Thoughts
Complaint handling backlogs rarely improve on their own. The longer complaints remain unresolved, the greater the regulatory, operational, and reputational risk becomes.
Companies that build scalable complaint handling and post-market surveillance systems early are typically:
- Better prepared for FDA inspections
- Faster at identifying quality issues
- More compliant operationally
- Less likely to face Warning Letters or remediation activities
Strong post-market processes are no longer optional — they are a core part of regulatory compliance and product lifecycle management.
Need Help Evaluating Your Complaint Handling Process?
RQMIS supports medical device, IVD, SaMD, AI-enabled, and combination product companies with complaint handling remediation, post-market surveillance support, CAPA integration, adverse event reporting, trend analysis, and FDA inspection readiness.
If your organization would like a Complaint Handling Gap Assessment, our regulatory and quality experts can help evaluate your current processes, identify operational bottlenecks, and support practical next steps before backlog issues become major FDA concerns.